PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease?

Prostate Specific Membrane Antigen Positron Emission Tomography (PSMA-PET) is routinely used for the staging of patients with prostate cancer, but data on response assessment are sparse and primarily stem from metastatic castration-resistant prostate cancer (mCRPC) patients treated with PSMA radioli...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Theranostics 2024-01, Vol.14 (9), p.3623-3633
Hauptverfasser:	Küper, Alina T, Kersting, David, Telli, Tugce, Herrmann, Ken, Rominger, Axel, Afshar-Oromieh, Ali, Lopes, Leonor, Karkampouna, Sofia, Shi, Kuangyu, Kim, Moon, Hadaschik, Boris, Darr, Christopher, Umutlu, Lale, Fendler, Wolfgang P, Seifert, Robert
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Aged, 80 and over Antigens, Surface - metabolism Dipeptides - therapeutic use Follow-Up Studies Gallium Isotopes Gallium Radioisotopes Glutamate Carboxypeptidase II - metabolism Heterocyclic Compounds, 1-Ring - therapeutic use Humans Lutetium - therapeutic use Male Middle Aged Positron Emission Tomography Computed Tomography - methods Positron-Emission Tomography - methods Prognosis Prostatic Neoplasms - diagnostic imaging Prostatic Neoplasms - pathology Prostatic Neoplasms, Castration-Resistant - diagnostic imaging Prostatic Neoplasms, Castration-Resistant - pathology Radiopharmaceuticals Research Paper Retrospective Studies Tumor Burden
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!